Cadmus Rich - Oct 28, 2021 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Medical Officer Head of R&D
Signature
/s/ Julie Feder
Stock symbol
AURA
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
4
Date filed
10/29/2021, 07:32 PM
Next filing
Nov 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +26.3K $0.00 26.3K Oct 28, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award +113K 113K Oct 28, 2021 Common stock 113K $14.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2 The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Remarks:

Chief Medical Officer Head of R&D